Amivantamab-Lazertinib for EGFR NSCLC Survival Rates
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily impact individuals with pre-existing cardiovascular disease who are considering or currently using semaglutide for weight loss.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
what Happened? A Closer look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who where treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33,indicating a 33% increased risk. Importantly, the trial population was specifically chosen for its high cardiovascular risk profile, including a history of heart attack, stroke, or peripheral artery disease.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.6 |
| Non-Fatal Stroke | 2.8 | 2.2 |
| Non-Fatal Heart Attack | 3.4 | 2.1 |
| MACE (Combined) | 6.5 | 4.9 |
Who is affected? Understanding the Risk Profile
These findings primarily impact individuals with pre-existing cardiovascular disease who are considering or currently using semaglutide for weight loss. Its crucial to differentiate this population from those with obesity *without* established heart conditions, where the risk-benefit profile may still be favorable. The SELECT trial did *not* include patients with type 2 diabetes, so the results cannot be directly extrapolated to that population.
The trial participants had a mean BMI of 32 kg/m2 and a history of established cardiovascular disease. This suggests the increased risk is not necessarily inherent to semaglutide itself, but rather a potential interaction with underlying cardiovascular vulnerabilities.
Why Does This Matter? The Implications for Clinical Practice
The SELECT trial results necessitate a more cautious approach to prescribing semaglutide,particularly in patients with known cardiovascular disease. Healthcare providers should thoroughly assess a patient’s cardiovascular risk factors *before* initiating treatment and carefully weigh the potential benefits against the newly identified risks. ongoing monitoring for cardiovascular symptoms is also essential.
This also highlights the importance of lifestyle interventions – diet and exercise – as foundational components of weight management. Medications like semaglutide should be considered adjuncts to, not replacements for, healthy lifestyle habits.
Timeline of events & Key Developments
- August 17, 2023: SELECT trial results publicly released.
- Ongoing: Further analysis of SELECT trial data to identify potential subgroups at higher risk.
- Future: Potential for additional trials to investigate the cardiovascular effects of semaglutide in different populations.